菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

Press Releases

WuXi Biologics Receives High CDP Leadership Ratings and “Leadership Award”
Jan. 17, 2023
WuXi Biologics Receives High CDP Leadership Ratings and “Leadership Award”

Shanghai, China, Jan. 17, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has earned high ratings from CDP for its corporate activities in response to climate change and water security. The company also received a “Leadership Award” at the “Awarding Ceremony of Outstanding Environmental Disclosure Company” held by CDP China.

 

CDP is an international non-profit organization that runs a global environmental impact disclosure system on behalf of institutional investors for companies’ activities related to climate change, forests and water security. In 2022, over 18,700 companies participated in CDP’s environmental disclosure. WuXi Biologics’ scores on both water security and climate change improved significantly from previous years, going to A- and B respectively, which makes the company enter the “leadership” level.

 

At the “Awarding Ceremony of Outstanding Environmental Disclosure Company” held by CDP China, WuXi Biologics also received a “Leadership Award” for demonstrating leadership in disclosing information, identifying and managing risks, addressing challenges, and setting significant, ambitious goals.

 

Dr. Chris Chen, WuXi Biologics’ CEO and Chairperson of the company’s Environmental, Social, and Governance (ESG) Committee, commented, “We are very proud to have received a leadership-level rating from CDP and the ‘Leadership Award,’ which recognize both our actions to combat climate change and our transparent environmental reporting. With the increasing demand for environmental transparency in the world, WuXi Biologics has responded with strong commitment and performance. We will continue to create value for investors and enable our global partners for the benefit of patients worldwide.”

 

Flora Wu, Director of CDP China, commented, “Climate change is already posing a real and increasing risk to companies and their supply chains. Companies have a fundamental role to play in securing a sustainable net-zero, deforestation-free and water-secure world. WuXi Biologics has taken a vital first step. I look forward to their continued dedication to transparency and action for the benefit of all people and the planet.”

 

To actively address climate change and protect water resources, WuXi Biologics set ambitious goals, formed clear strategies, and made down-to-earth roadmaps, and, as a result, has seen meaningful achievements. The company has integrated low-carbon concepts into all aspects of design, construction and operation of its new sites. In daily management, a cross-function team works on implementing technological innovation and optimizing processes for research, development, manufacturing, logistics, and waste disposal. The aim is to continuously enhance energy efficiency, reduce energy use and carbon emission, and improve sustainability performance in the areas of energy, water, biodiversity and waste. For example, all newly-released sites are equipped with water-recycling systems and each one is expected to save nearly 100 tons of water every day. In addition, mechanisms for collecting rainwater for irrigation will allow a new site to reduce water usage by 4000 tons a year.

 

About WuXi Biologics

 

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

 

With over 10,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions.

 

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

 

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

 

Contacts

 

Media

PR@wuxibiologics.com

 

ESG

ESG@wuxibiologics.com